• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Turn Therapeutics Inc. - Common Stock (NQ:TTRX)

10.18 +0.03 (+0.30%)
Delayed Quote Updated: 4:00 PM EDT, Oct 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 113,120
Open 10.05
Bid (Size) 9.690 (300)
Ask (Size) 10.50 (200)
Prev. Close 10.15
Today's Range 9.830 - 10.47
52wk Range 2.570 - 16.45
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
U.S. Bancorp | BTIG to Host Turn Therapeutics for Virtual Fireside Chat
October 21, 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
September 10, 2026
From Turn Therapeutics Inc.
Via Business Wire

Performance

52-Week Range 38.1% below 52-week high
10.18
2.5752W Low 16.4552W High
1 Week 11.4% below 1-week high
9.831W Low 11.491W High

Turn Therapeutics Inc. - Common Stock (TTRX) traded between $2.57 and $16.45 over the past 52 weeks and last traded at $10.18, 38.1% below its 52-week high. Over the past week it ranged between $9.83 and $11.49.

Past 12 Months
-3.7%
-33.4%
+7.4%
+203.9%
+117.1%
+143.5%
1W -$0.39
1M -$5.11
3M +$0.70
6M +$6.83
YTD +$5.49
1Y +$6.00

TTRX was +143.5% over the past year, +203.9% over six months, +117.1% year to date, -3.7% in the last week.

12 Months vs Market
TTRX
+143.5%
DIA
+13.3%
SPY
+14.4%
QQQ
+16.3%
IWM
+13.7%

Over the past 12 months TTRX returned +143.5% versus DIA (Dow) +13.3%, SPY (S&P 500) +14.4%, QQQ (Nasdaq 100) +16.3% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 1.10× 3-mo avg
Today 113,120 3-mo avg 103.2K
1W
77.2K
1M
101.2K
3M
103.2K
6M
88.3K
YTD
66.9K
1Y
72.6K

TTRX most recently traded 113,120 shares against a 3-month average daily volume of 103.2K.

More News

Read More
News headline image
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer
September 09, 2026
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch
August 20, 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results
August 12, 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026
July 28, 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout ↗
July 11, 2026
Via MarketBeat
News headline image
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis
July 07, 2026
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis
July 06, 2026
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis
June 01, 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model
May 27, 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026
May 19, 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead
May 18, 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
May 11, 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
March 31, 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group
March 24, 2026
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs
February 17, 2026
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences
February 09, 2026
From Turn Therapeutics Inc.
Via Business Wire
News headline image
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From Turn Therapeutics, Inc.
Via Business Wire
News headline image
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors
January 07, 2026
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
November 13, 2025
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online Magazine
November 11, 2025
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.
November 11, 2025
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate Communications
November 04, 2025
From Turn Therapeutics
Via GlobeNewswire
News headline image
Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor Medline
October 30, 2025
From Turn Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Turn Therapeutics Inc. - Common Stock publicly traded?
Yes, Turn Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Turn Therapeutics Inc. - Common Stock trade on?
Turn Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Turn Therapeutics Inc. - Common Stock?
The ticker symbol for Turn Therapeutics Inc. - Common Stock is TTRX on the Nasdaq Stock Market
What is the current price of Turn Therapeutics Inc. - Common Stock?
The current price of Turn Therapeutics Inc. - Common Stock is 10.18
When was Turn Therapeutics Inc. - Common Stock last traded?
The last trade of Turn Therapeutics Inc. - Common Stock was at 10/22/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap